



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74894

Title: Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03733594

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2022-01-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-11 02:45

Reviewer performed review: 2022-01-18 03:58

Review time: 7 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This is a very clinically significant work. The authors elucidated the effect of SGLT2-I on liver inflammation, fatty changes and liver fibrosis in T2DM patients with NAFLD through 24 weeks of clinical observation, but there are several issues that the authors need to pay attention to: 1) The results of the article figure1D showed that SGLT2-I had a positive effect on weight loss compared with baseline, but one study showed that 3-5% weight loss (diet, exercise, weight loss) improved liver steatosis in NAFLD patients without additional medication, so is there an additional non-pharmacological intervention effect during 6 months in patients taking the drug in this trial? (Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Hannah WN Jr, Harrison SA Clin Liver Dis. 2016 May; 20 (2): 339-50.) 2) Whether PS matching is performed in the baseline analysis of SGLT2-I and the other group? 3) It does not seem to be seen in the article whether there is a description of adverse drug events?



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74894

Title: Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00225294

Position: Editorial Board

Academic degree: PhD

Professional title: Full Professor

Reviewer's Country/Territory: Spain

Author's Country/Territory: Italy

Manuscript submission date: 2022-01-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-13 07:57

Reviewer performed review: 2022-01-21 08:14

Review time: 8 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This is an essentially confirmatory work on the beneficial effects of the use of SGLT2 inhibitors vs other alternatives in the treatment of T2D and NAFLD. The cohort, although reduced, is quite consistent in the responses to these inhibitors (glyflosins). In addition, the authors provide data on inflammatory and ROS markers, as well as a validation of the extent of hepatic fibrosis (fibrosan). Although the novelty of this study is reduced, it may contribute to re-inforce studies on this field.